scanX
Emcure Pharmaceuticals
add_icon

Emcure Pharmaceuticals

2,009.60
+10.90
(0.55%)
Market Cap
38,113.98 Cr
PE Ratio
37.18
Volume
2,14,106.00
Day High - Low
2,023.00 - 1,983.30
52W High-Low
2,048.00 - 1,260.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
38,113.98 Cr
EPS
48.77
PE Ratio
37.18
PB Ratio
7.65
Book Value
260.97
EBITDA
1,833.20
Dividend Yield
0.18 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
15.24
Debt to Equity
0.45
Analyst Rating and Forecast
- By Refinitiv from7 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+85.71 %
+85.71 %
Hold
Hold+14.29 %
+14.29 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Emcure Pharma Gets US FDA Nod for Gujarat Plant4 days ago
Emcure Pharmaceuticals receives US FDA approval for its Sanand formulations plant in Gujarat, marking a significant regulatory milestone for the company.
positive
Jefferies Maintains Buy on Emcure Pharma, TP ₹2,3205 days ago
Jefferies reiterates Buy on Emcure Pharma with ₹2,320 target; 10%/12% revenue/EBITDA beats, domestic growth at 10% YoY, and 6% FY27-29 EPS upgrade.
neutral
Emcure Pharma Q1FY27 Earnings Call Audio5 days ago
Emcure Pharmaceuticals Limited has released the audio recording of its Q1 FY27 earnings call, held on August 06, 2026, in compliance with SEBI regulations.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,944.00
#1 4,66,430.72
38.42
#1 61,673.90
12.69
#1 11,565
26.53
51.65
Divis Laboratories
8,600.00
2,28,302.98
77.48
11,067.00
13.95
2,568
65.50
77.85
Torrent Pharmaceuticals
4,893.00
1,86,113.99
85.88
13,886.20
20.34
2,138
3.28
49.55
Zydus Life Science
1,205.00
1,21,251.20
25.63
27,657.90
17.64
5,026
-34.90
70.55
Cipla
1,463.00
1,18,187.77
35.19
29,044.60
2.24
3,870
-39.18
55.73
Lupin
2,281.00
1,04,294.74
#1 18.76
29,038.90
#1 26.75
5,356
16.00
34.34
Mankind Pharma
2,433.10
1,00,486.05
48.44
14,636.40
14.85
1,938
29.13
43.28
Dr Reddys Laboratories
1,200.00
1,00,160.29
31.59
35,058.60
3.90
4,158
-69.10
49.25
Laurus Labs
1,850.00
99,873.47
92.17
6,867.80
22.01
890
#1 123.93
77.62
Aurobindo Pharma
1,667.00
95,915.50
25.70
34,145.20
5.56
3,503
25.21
65.52
Growth Rate
Revenue Growth
15.49 %
Net Income Growth
26.44 %
Cash Flow Change
-22.38 %
ROE
-9.82 %
ROCE
-1.72 %
EBITDA Margin (Avg.)
2.79 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1,571
1,664
1,697
1,783
1,839
2,038
1,967
2,121
2,104
2,273
2,365
2,484
2,583
Expenses
1,261
1,337
1,381
1,460
1,479
1,621
1,608
1,724
1,687
1,794
1,909
1,990
2,048
EBITDA
311
327
316
323
360
417
359
397
417
479
456
494
535
Operating Profit %
19 %
20 %
17 %
18 %
19 %
19 %
18 %
19 %
20 %
21 %
19 %
19 %
21 %
Depreciation
67
70
84
91
94
97
97
97
100
105
105
106
110
Interest
52
59
61
66
59
46
32
39
27
33
38
46
32
Profit Before Tax
191
198
171
167
207
273
230
261
291
341
314
341
394
Tax
50
52
51
46
55
72
74
63
76
90
82
97
101
Net Profit
141
146
120
121
153
202
156
197
215
251
231
244
293
EPS in ₹
7.21
7.70
6.27
6.36
7.95
10.23
8.12
9.97
10.92
12.85
12.16
12.84
15.50
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Fixed Assets
2,049
2,247
2,382
2,188
2,044
2,147
3,125
3,197
Current Assets
2,335
2,453
2,703
3,718
3,424
3,836
4,260
4,556
Capital Work in Progress
531
581
485
302
320
411
159
177
Investments
0
0
0
0
25
25
318
95
Other Assets
2,667
2,817
3,137
4,318
3,674
4,089
4,204
4,763
Total Equity & Liabilities
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Current Liabilities
2,336
2,543
2,920
3,408
2,965
3,019
3,211
2,668
Non Current Liabilities
1,157
1,201
1,100
1,031
985
1,004
1,474
923
Total Equity
1,755
1,900
1,984
2,368
2,114
2,650
3,122
4,642
Reserve & Surplus
1,520
1,654
1,731
2,092
1,807
2,320
2,771
4,257
Share Capital
181
181
181
181
181
181
181
190
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-700
32
259
42
134
219
-58
Investing Activities
-409
-168
-257
-575
-468
-715
-96
Operating Activities
444
500
704
768
747
1,097
852
Financing Activities
-735
-301
-189
-152
-145
-164
-814
Above figures are in Rs. Crores

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Promoter
78.08 %
78.08 %
77.94 %
77.92 %
77.91 %
77.88 %
77.87 %
77.87 %
77.83 %
FIIs
1.76 %
2.91 %
3.05 %
3.07 %
2.86 %
3.29 %
3.59 %
3.35 %
4.88 %
DIIs
3.34 %
3.96 %
3.87 %
3.44 %
2.84 %
4.37 %
6.10 %
6.10 %
8.46 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.73 %
5.00 %
5.14 %
5.51 %
5.95 %
6.24 %
6.46 %
6.46 %
6.45 %
Others
9.10 %
10.04 %
10.00 %
10.06 %
10.44 %
8.22 %
5.98 %
6.22 %
2.38 %
No of Share Holders
4,98,006
1,52,914
1,43,449
1,39,671
1,33,549
1,26,169
1,18,863
1,22,189
1,24,991

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 3 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.19 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Nov 2024 1,406.40 1,444.25
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Feb 2025 1,345.75 1,249.80
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 22 May 2025 1,036.35 1,073.60
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Aug 2025 1,405.55 1,421.25
14 Aug 2025 DIVIDEND Dividend
₹ 3.00 /share
 14 Aug 2025 1,073.60 1,453.80
28 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 28 Aug 2025 1,408.15 1,468.60
11 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 11 Nov 2025 1,318.00 1,426.60
04 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 04 Feb 2026 1,557.90 1,505.75
05 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 May 2026 1,636.30 1,785.15
06 Aug 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Aug 2026 1,810.10 1,959.00

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome2 hrs ago
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 20154 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome5 days ago
Intimation Of Date Of The 45Th Annual General Meeting And Record Date6 days ago
Announcement under Regulation 30 (LODR)-Change in Management6 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation6 days ago
Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 20266 days ago
Board Meeting Outcome for Outcome Of Board Meeting Held On August 06 20266 days ago
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update On Completion Of Acquisition Of Shares Of Gennova Biopharmaceuticals Limited. Jul 22, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJul 21, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 15, 2026
Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2026Jul 15, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 13, 2026
Announcement under Regulation 30 (LODR)-AcquisitionJul 13, 2026
Announcement under Regulation 30 (LODR)-RestructuringJul 11, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2026
Announcement under Regulation 30 (LODR)-AcquisitionJul 03, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJun 30, 2026
Closure of Trading WindowJun 29, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 19, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJun 12, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 27, 2026
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - US FDA Inspection At Our Formulations Facility Located At Sanand Ahmedabad Gujarat India.May 16, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 11, 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingMay 08, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 05, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 05, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 05, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationMay 05, 2026
Corporate Action-Board approves DividendMay 05, 2026
Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31 2026May 05, 2026
Board Meeting Outcome for Outcome Of The Board Meeting Held On May 05 2026May 05, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 28, 2026
Board Meeting Intimation for Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31 2026Apr 28, 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update On Appointment Of Independent DirectorApr 27, 2026
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 27, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 27, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
2.46%
-43425
-1.14%
-0.92%
Samco Small Cap Fund Direct-Growth
2.17%
18903
2.17%
2.17%
JioBlackRock Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
-5959
-0.30%
-0.29%
JioBlackRock Sector Rotation Fund Direct-Growth
0.00%
-472
-0.05%
0.00%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.00%
-103
-0.03%
-0.03%
Zerodha Nifty MidSmallcap400 50:50 Index Fund Direct-Growth
0.16%
22
0.01%
0.03%
DSP Nifty Smallcap 250 Index Fund Direct-Growth
0.31%
18
0.01%
0.02%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.11%
-4
0.00%
0.01%
Navi Nifty MidSmallcap 400 Index Fund Direct-Growth
0.11%
-1
0.01%
0.01%
Groww Aggressive Hybrid Fund Direct-Growth
0.00%
0
0.00%
0.00%
Groww Value Fund Direct-Growth
0.00%
0
0.00%
0.00%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
1.32%
0
0.00%
0.16%
Angel One Nifty Total Market Index Fund Direct-Growth
0.03%
0
0.00%
0.00%
Axis Balanced Advantage Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Business Cycles Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Equity Savings Fund Direct-Growth
0.46%
0
0.00%
0.02%
Axis Multi Asset Allocation Direct Plan-Growth
0.48%
0
0.00%
0.01%
Axis Nifty 500 Index Fund Direct-Growth
0.03%
0
0.00%
0.00%
Axis Small Cap Fund Direct-Growth
0.53%
0
0.00%
0.02%
Bajaj Finserv Flexi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bajaj Finserv Healthcare Fund Direct-Growth
4.37%
0
0.00%
0.01%
Bajaj Finserv Large and Mid Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.42%
0
0.00%
0.02%
Bandhan Flexi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Healthcare Fund Direct-Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
66.42
ATR(14)
Less Volatile
56.99
STOCH(9,6)
Neutral
68.02
STOCH RSI(14)
Neutral
79.14
MACD(12,26)
Bullish
4.94
ADX(14)
Strong Trend
38.85
UO(9)
Bearish
44.11
ROC(12)
Uptrend And Accelerating
6.26
WillR(14)
Neutral
-25.60
Bearish
3
Neutral
3
Bullish
3

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes...more
Listing Date
10 Jul, 2024(2 Years, 1 Month, 2 Days)
Website
https://www.emcure.com
Chairperson NameSATISH RAMANLAL MEHTA
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104